Positioning of second-line treatment for advanced gastric and gastroesophageal junction adenocarcinoma
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Positioning of second-line treatment for advanced gastric and gastroesophageal junction adenocarcinoma
Authors
Keywords
-
Journal
Cancer Medicine
Volume 5, Issue 12, Pages 3464-3474
Publisher
Wiley
Online
2016-10-24
DOI
10.1002/cam4.941
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Doublet Versus Single Agent as Second-Line Treatment for Advanced Gastric Cancer
- (2016) Yong Zhang et al. MEDICINE
- Not only chemotherapy in the second-line treatment of metastatic gastric cancer
- (2014) E. Vasile et al. ANNALS OF ONCOLOGY
- Phase II trial of miniDOX (reduced dose docetaxel–oxaliplatin–capecitabine) in “suboptimal” patients with advanced gastric cancer (AGC). TTD 08-02
- (2014) F. Rivera et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Management of gastric cancer
- (2014) Geoffrey Y. Ku et al. CURRENT OPINION IN GASTROENTEROLOGY
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012
- (2014) Jacques Ferlay et al. INTERNATIONAL JOURNAL OF CANCER
- Prospective, Randomized, Multicenter, Phase III Study of Fluorouracil, Leucovorin, and Irinotecan Versus Epirubicin, Cisplatin, and Capecitabine in Advanced Gastric Adenocarcinoma: A French Intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) Study
- (2014) Rosine Guimbaud et al. JOURNAL OF CLINICAL ONCOLOGY
- Ramucirumab plus paclitaxel versus placebo plus paclitaxel in patients with previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (RAINBOW): a double-blind, randomised phase 3 trial
- (2014) Hansjochen Wilke et al. LANCET ONCOLOGY
- Chemotherapy or Targeted Therapy as Second-Line Treatment of Advanced Gastric Cancer. A Systematic Review and Meta-Analysis of Published Studies
- (2014) Roberto Iacovelli et al. PLoS One
- Medical management of gastric cancer: A 2014 update
- (2014) Elena Elimova WORLD JOURNAL OF GASTROENTEROLOGY
- Second-line chemotherapy versus supportive cancer treatment in advanced gastric cancer: a meta-analysis
- (2013) H. S. Kim et al. ANNALS OF ONCOLOGY
- Gastric cancer: ESMO-ESSO-ESTRO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2013) T. Waddell et al. ANNALS OF ONCOLOGY
- Geographic differences in approach to advanced gastric cancer: Is there a standard approach?
- (2013) Richard Kim et al. CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
- Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012
- (2013) J. Ferlay et al. EUROPEAN JOURNAL OF CANCER
- Optimal chemotherapy for advanced gastric cancer: is there a global consensus?
- (2013) Florian Lordick et al. Gastric Cancer
- Randomized, Open-Label, Phase III Study Comparing Irinotecan With Paclitaxel in Patients With Advanced Gastric Cancer Without Severe Peritoneal Metastasis After Failure of Prior Combination Chemotherapy Using Fluoropyrimidine Plus Platinum: WJOG 4007 Trial
- (2013) Shuichi Hironaka et al. JOURNAL OF CLINICAL ONCOLOGY
- Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial
- (2013) Charles S Fuchs et al. LANCET
- Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial
- (2013) Tom Waddell et al. LANCET ONCOLOGY
- Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
- (2013) Florian Lordick et al. LANCET ONCOLOGY
- Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
- (2013) Hugo E R Ford et al. LANCET ONCOLOGY
- The safety and efficacy of fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) combination in the front-line treatment for patients with advanced gastric or gastroesophageal adenocarcinoma: phase II trial
- (2013) Abeer Hussien Anter et al. MEDICAL ONCOLOGY
- Optimal indications for second-line chemotherapy in advanced gastric cancer
- (2012) Hiroko Hasegawa et al. ANTI-CANCER DRUGS
- Geographic difference in safety and efficacy of systemic chemotherapy for advanced gastric or gastroesophageal carcinoma: a meta-analysis and meta-regression
- (2012) Chiun Hsu et al. Gastric Cancer
- Overall survival benefits for irinotecan-containing regimens as first-line treatment for advanced gastric cancer: An updated meta-analysis of ten randomized controlled trials
- (2012) Wei-Xiang Qi et al. INTERNATIONAL JOURNAL OF CANCER
- Epidemiology and Risk Factors for Gastroesophageal Junction Tumors: Understanding the Rising Incidence of This Disease
- (2012) Matthew F. Buas et al. SEMINARS IN RADIATION ONCOLOGY
- Advanced gastric cancer: Is there enough evidence to call second-line therapy standard?
- (2012) Hendrik-Tobias Arkenau WORLD JOURNAL OF GASTROENTEROLOGY
- Management of advanced gastric cancer
- (2012) Timothy J Price et al. Expert Review of Gastroenterology & Hepatology
- Survival advantage for irinotecan versus best supportive care as second-line chemotherapy in gastric cancer – A randomised phase III study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
- (2011) Peter C. Thuss-Patience et al. EUROPEAN JOURNAL OF CANCER
- Bevacizumab in Combination With Chemotherapy As First-Line Therapy in Advanced Gastric Cancer: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
- (2011) Atsushi Ohtsu et al. JOURNAL OF CLINICAL ONCOLOGY
- Neutropenia as a prognostic factor in advanced gastric cancer patients undergoing second-line chemotherapy with weekly paclitaxel
- (2010) K. Shitara et al. ANNALS OF ONCOLOGY
- A prognostic model in patients treated for metastatic gastric cancer with second-line chemotherapy
- (2010) D. Kanagavel et al. ANNALS OF ONCOLOGY
- Docetaxel/cisplatin followed by FOLFIRI versus the reverse sequence in metastatic gastric cancer
- (2010) Jung A. Kim et al. CANCER CHEMOTHERAPY AND PHARMACOLOGY
- Clinical Trials and Approval of Anti-cancer Agents
- (2010) M. Iwasaki et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial
- (2010) Jaffer A. Ajani et al. JOURNAL OF CLINICAL ONCOLOGY
- Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
- (2010) Yung-Jue Bang et al. LANCET
- Capecitabine/cisplatin versus 5-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial
- (2009) Y.-K. Kang et al. ANNALS OF ONCOLOGY
- Randomized phase III study comparing irinotecan combined with 5-fluorouracil and folinic acid to cisplatin combined with 5-fluorouracil in chemotherapy naive patients with advanced adenocarcinoma of the stomach or esophagogastric junction
- (2008) M. Dank et al. ANNALS OF ONCOLOGY
- Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie
- (2008) S.-E. Al-Batran et al. ANNALS OF ONCOLOGY
- Second-line chemotherapy for patients with advanced gastric cancer: who may benefit?
- (2008) V Catalano et al. BRITISH JOURNAL OF CANCER
- Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie
- (2008) Salah-Eddin Al-Batran et al. JOURNAL OF CLINICAL ONCOLOGY
- S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial
- (2008) Wasaburo Koizumi et al. LANCET ONCOLOGY
- Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer
- (2008) David Cunningham et al. NEW ENGLAND JOURNAL OF MEDICINE
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now